GT Biopharma, Inc.
GTBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $10 | $5 | $6 |
| - Cash | $3 | $5 | $2 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $5 | $3 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.83 | -0.55 | -0.33 | -1.99 |
| % Growth | -50.9% | -66.7% | 83.4% | – |
| Operating Cash Flow | -$4 | -$3 | -$2 | -$2 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$3 | -$2 | -$2 |